102 related articles for article (PubMed ID: 2551306)
1. Possible involvement of the dopaminergic system in the mode of action of the potential antidepressant trazium esilate.
Gyertyán I; Petöcz L; Bajnógel J; Szücs Z; Hegedüs M; Gyüre K; Gacsályi I; Krizsán D; Fekete MI
Arzneimittelforschung; 1989 Jul; 39(7):775-81. PubMed ID: 2551306
[TBL] [Abstract][Full Text] [Related]
2. Studies on the participation of the dopaminergic system in the central effects of chronically administered antidepressant drugs.
Kozyrska C; Zebrowska-Lupina I
Pol J Pharmacol Pharm; 1983; 35(2):115-26. PubMed ID: 6684769
[TBL] [Abstract][Full Text] [Related]
3. [Differences in the mechanisms of the stimulant and antidepressive effects of nomifensine].
Chermat R; Poncelet M; Simon P
J Pharmacol; 1985; 16(1):7-13. PubMed ID: 2860270
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of McN-5707 as a potential antidepressant.
Shank RP; Gardocki JF; Schneider CR; Vaught JL; Setler PE; Maryanoff BE; McComsey DF
J Pharmacol Exp Ther; 1987 Jul; 242(1):74-84. PubMed ID: 3039115
[TBL] [Abstract][Full Text] [Related]
5. On the mechanism of antidepressant-like action of berberine chloride.
Kulkarni SK; Dhir A
Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of lortalamine, a new potent non-tricyclic antidepressant.
Depin JC; Betbeder-Matibet A; Bonhomme Y; Muller AJ; Berthelon JJ
Arzneimittelforschung; 1985; 35(11):1655-62. PubMed ID: 4091869
[TBL] [Abstract][Full Text] [Related]
7. Effects of dextromethorphan on dopamine dependent behaviours in rats.
Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
[TBL] [Abstract][Full Text] [Related]
8. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
Khisti RT; Deshpande LS; Chopde CT
Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
[TBL] [Abstract][Full Text] [Related]
9. EGYT-2509 a novel neuroleptic agent without extrapyramidal and endocrine side effects.
Gacsályi I; Petöcz L; Fekete MI; Bükkfálvi B; Görgenyi F; Arató M
Pol J Pharmacol Pharm; 1988; 40(6):613-9. PubMed ID: 2908364
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
11. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor.
Izzo E; Sanna PP; Koob GF
Pharmacol Biochem Behav; 2005 Aug; 81(4):701-8. PubMed ID: 16005056
[TBL] [Abstract][Full Text] [Related]
12. The effect of alpha-adrenolytics on central action of agonists and antagonists of dopaminergic system.
Zebrowska-Lupina I
Pol J Pharmacol Pharm; 1977; 29(4):393-404. PubMed ID: 20609
[TBL] [Abstract][Full Text] [Related]
13. The influence of antineoplaston A5 on the central dopaminergic structures.
Juszkiewicz M; Chodkowska A; Burzynski SR; Feldo M; Majewska B; Kleinrok Z
Drugs Exp Clin Res; 1994; 20(4):161-7. PubMed ID: 7813388
[TBL] [Abstract][Full Text] [Related]
14. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant profile of 9-methyl-2[-3-(4-phenyl-1-piperazinylpropyl)]-1,2,3,4-tetrahydro-beta- carbolin-1-one (B-193).
Wiczyńska B; Antkiewicz-Michaluk L; Pilc A; Chojnacka-Wójcik E; Przegaliński E
Pol J Pharmacol Pharm; 1989; 41(4):331-44. PubMed ID: 2636891
[TBL] [Abstract][Full Text] [Related]
18. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
[TBL] [Abstract][Full Text] [Related]
19. Some central effects of angiotensin II. Interactions with dopaminergic transmission.
Georgiev V; György L; Getova D; Markovska V
Acta Physiol Pharmacol Bulg; 1985; 11(4):19-26. PubMed ID: 3012944
[TBL] [Abstract][Full Text] [Related]
20. Central action of phenylethylamine in rats.
Jagiełło-Wójtowicz E
Pol J Pharmacol Pharm; 1981; 33(1):59-71. PubMed ID: 7196039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
